This startup develops rapid drug testing technology that analyzes minuscule volumes of bodily fluids using nanostructured silicon chips. Their platform detects drug metabolites quickly, from sample preparation to results, enabling medical professionals to efficiently screen for tiny drug molecules.
Funding
Funding not disclosed
Founders
Product
Problem
Current drug testing methods often require a two-stage process and can be time-consuming and costly, especially when rapid results are needed for immediate decision-making. Traditional methods may also involve invasive sample collection and lengthy analysis times, limiting their applicability in point-of-care or field settings.
Solution
NanoFynd offers a rapid drug testing platform that utilizes nanostructured silicon chips and MALDI-TOF Mass Spectrometry to detect drug metabolites in minute volumes of bodily fluids, such as saliva. This lab-on-a-chip technology enables point-of-collection confirmatory testing, reducing the need for traditional two-stage processes and delivering results in minutes. The platform's nano-coated substrate enhances the detection of a wide range of drugs, streamlining the testing process and lowering expenses. By offering a less invasive testing option with faster analysis times, NanoFynd empowers various industries to prioritize safety and make informed decisions more effectively.
Target Audience
NanoFynd serves forensic science and law enforcement, workplace drug testing programs, rehabilitation centers, healthcare facilities, customs and border control agencies, sports organizations, medical research institutions, transportation industries, and correctional facilities.
Features
- Patented nanostructured silicon chips for enhanced drug metabolite detection
- MALDI-TOF Mass Spectrometry for rapid analysis of bodily fluids
- Detection of drug metabolites in microliter volumes
- Non-invasive sample collection using oral fluid or potentially breath samples
- Streamlined testing process eliminating the need for two-stage testing
- Broadened range of detectable drugs compared to current DIOS systems